Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study

Philippe Armand; Haesook T. Kim; Mei-Jie Zhang; Waleska S. Perez; Paola S. Dal Cin; Thomas R. Klumpp; Edmund K. Waller; Mark R. Litzow; Jane L. Liesveld; Hillard M. Lazarus; Andrew S. Artz; Vikas Gupta; Bipin N. Savani; Philip L. McCarthy; Jean-Yves Cahn; Harry C. Schouten; Juergen Finke; Edward D. Ball; Mahmoud D. Aljurf; Corey S. Cutler; Jacob M. Rowe; Joseph H. Antin; Luis M. Isola; Paolo Di Bartolomeo; Bruce M. Camitta; Alan M. Miller; Mitchell S. Cairo; Keith Stockerl-Goldstein; Jorge Sierra; M. Lynn Savoie; Joerg Halter; Patrick J. Stiff; Chadi Nabhan; Ann A. Jakubowski; Donald W. Bunjes; Effie W. Petersdorf; Steven M. Devine; Richard I. Maziarz; Martin Bornhauser; Victor A. Lewis; David I. Marks; Christopher N. Bredeson; Robert J. Soiffer; Daniel J. Weisdorf

doi:10.1016/j.bbmt.2011.07.024

Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study

Philippe Armand^*, Haesook T. Kim, Mei-Jie Zhang, Waleska S. Perez, Paola S. Dal Cin, Thomas R. Klumpp, Edmund K. Waller, Mark R. Litzow, Jane L. Liesveld, Hillard M. Lazarus, Andrew S. Artz, Vikas Gupta, Bipin N. Savani, Philip L. McCarthy, Jean-Yves Cahn, Harry C. Schouten, Juergen Finke, Edward D. Ball, Mahmoud D. Aljurf, Corey S. CutlerJacob M. Rowe, Joseph H. Antin, Luis M. Isola, Paolo Di Bartolomeo, Bruce M. Camitta, Alan M. Miller, Mitchell S. Cairo, Keith Stockerl-Goldstein, Jorge Sierra, M. Lynn Savoie, Joerg Halter, Patrick J. Stiff, Chadi Nabhan, Ann A. Jakubowski, Donald W. Bunjes, Effie W. Petersdorf, Steven M. Devine, Richard I. Maziarz, Martin Bornhauser, Victor A. Lewis, David I. Marks, Christopher N. Bredeson, Robert J. Soiffer, Daniel J. Weisdorf

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials. American Society for Blood and Marrow Transplantation.

Original language	English
Pages (from-to)	280-288
Journal	Biology of Blood and Marrow Transplantation
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.bbmt.2011.07.024
Publication status	Published - Feb 2012

Keywords

AML
SCT
Karyotype

Access to Document

10.1016/j.bbmt.2011.07.024Licence: CC BY-NC-ND

Cite this

Armand, P., Kim, H. T., Zhang, M.-J., Perez, W. S., Dal Cin, P. S., Klumpp, T. R., Waller, E. K., Litzow, M. R., Liesveld, J. L., Lazarus, H. M., Artz, A. S., Gupta, V., Savani, B. N., McCarthy, P. L., Cahn, J.-Y., Schouten, H. C., Finke, J., Ball, E. D., Aljurf, M. D., ... Weisdorf, D. J. (2012). Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 18(2), 280-288. https://doi.org/10.1016/j.bbmt.2011.07.024

@article{202593877eb14f9487851a08f81b164e,

title = "Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study",

abstract = "Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials. American Society for Blood and Marrow Transplantation.",

keywords = "AML, SCT, Karyotype",

author = "Philippe Armand and Kim, {Haesook T.} and Mei-Jie Zhang and Perez, {Waleska S.} and {Dal Cin}, {Paola S.} and Klumpp, {Thomas R.} and Waller, {Edmund K.} and Litzow, {Mark R.} and Liesveld, {Jane L.} and Lazarus, {Hillard M.} and Artz, {Andrew S.} and Vikas Gupta and Savani, {Bipin N.} and McCarthy, {Philip L.} and Jean-Yves Cahn and Schouten, {Harry C.} and Juergen Finke and Ball, {Edward D.} and Aljurf, {Mahmoud D.} and Cutler, {Corey S.} and Rowe, {Jacob M.} and Antin, {Joseph H.} and Isola, {Luis M.} and {Di Bartolomeo}, Paolo and Camitta, {Bruce M.} and Miller, {Alan M.} and Cairo, {Mitchell S.} and Keith Stockerl-Goldstein and Jorge Sierra and Savoie, {M. Lynn} and Joerg Halter and Stiff, {Patrick J.} and Chadi Nabhan and Jakubowski, {Ann A.} and Bunjes, {Donald W.} and Petersdorf, {Effie W.} and Devine, {Steven M.} and Maziarz, {Richard I.} and Martin Bornhauser and Lewis, {Victor A.} and Marks, {David I.} and Bredeson, {Christopher N.} and Soiffer, {Robert J.} and Weisdorf, {Daniel J.}",

year = "2012",

month = feb,

doi = "10.1016/j.bbmt.2011.07.024",

language = "English",

volume = "18",

pages = "280--288",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Science",

number = "2",

}

Armand, P, Kim, HT, Zhang, M-J, Perez, WS, Dal Cin, PS, Klumpp, TR, Waller, EK, Litzow, MR, Liesveld, JL, Lazarus, HM, Artz, AS, Gupta, V, Savani, BN, McCarthy, PL, Cahn, J-Y, Schouten, HC, Finke, J, Ball, ED, Aljurf, MD, Cutler, CS, Rowe, JM, Antin, JH, Isola, LM, Di Bartolomeo, P, Camitta, BM, Miller, AM, Cairo, MS, Stockerl-Goldstein, K, Sierra, J, Savoie, ML, Halter, J, Stiff, PJ, Nabhan, C, Jakubowski, AA, Bunjes, DW, Petersdorf, EW, Devine, SM, Maziarz, RI, Bornhauser, M, Lewis, VA, Marks, DI, Bredeson, CN, Soiffer, RJ & Weisdorf, DJ 2012, 'Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study', Biology of Blood and Marrow Transplantation, vol. 18, no. 2, pp. 280-288. https://doi.org/10.1016/j.bbmt.2011.07.024

Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study. / Armand, Philippe; Kim, Haesook T.; Zhang, Mei-Jie et al.
In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 2, 02.2012, p. 280-288.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study

AU - Armand, Philippe

AU - Kim, Haesook T.

AU - Zhang, Mei-Jie

AU - Perez, Waleska S.

AU - Dal Cin, Paola S.

AU - Klumpp, Thomas R.

AU - Waller, Edmund K.

AU - Litzow, Mark R.

AU - Liesveld, Jane L.

AU - Lazarus, Hillard M.

AU - Artz, Andrew S.

AU - Gupta, Vikas

AU - Savani, Bipin N.

AU - McCarthy, Philip L.

AU - Cahn, Jean-Yves

AU - Schouten, Harry C.

AU - Finke, Juergen

AU - Ball, Edward D.

AU - Aljurf, Mahmoud D.

AU - Cutler, Corey S.

AU - Rowe, Jacob M.

AU - Antin, Joseph H.

AU - Isola, Luis M.

AU - Di Bartolomeo, Paolo

AU - Camitta, Bruce M.

AU - Miller, Alan M.

AU - Cairo, Mitchell S.

AU - Stockerl-Goldstein, Keith

AU - Sierra, Jorge

AU - Savoie, M. Lynn

AU - Halter, Joerg

AU - Stiff, Patrick J.

AU - Nabhan, Chadi

AU - Jakubowski, Ann A.

AU - Bunjes, Donald W.

AU - Petersdorf, Effie W.

AU - Devine, Steven M.

AU - Maziarz, Richard I.

AU - Bornhauser, Martin

AU - Lewis, Victor A.

AU - Marks, David I.

AU - Bredeson, Christopher N.

AU - Soiffer, Robert J.

AU - Weisdorf, Daniel J.

PY - 2012/2

Y1 - 2012/2

N2 - Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials. American Society for Blood and Marrow Transplantation.

AB - Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar nonrelapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials. American Society for Blood and Marrow Transplantation.

KW - AML

KW - SCT

KW - Karyotype

U2 - 10.1016/j.bbmt.2011.07.024

DO - 10.1016/j.bbmt.2011.07.024

M3 - Article

C2 - 21810400

SN - 1083-8791

VL - 18

SP - 280

EP - 288

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 2

ER -